The American Academy of Family Physicians has published a clinical review titled "Melanoma: Diagnosis and Treatment," putting a primary-care framing on a disease that dermatologists manage at the specialist end of the referral chain.

The AAFP issued the guidance as a resource for family physicians, the clinicians most likely to see a suspicious pigmented lesion first. The review walks through how melanoma gets flagged, worked up and treated, from the initial skin exam through biopsy decisions and onward to management of confirmed disease.

Why does a family-medicine review matter to dermatology readers?

Because the front door matters. A large share of melanomas are first noticed — or first missed — in primary care. Reviews like this one shape how lesions get triaged before they reach a dermatology clinic, and they set expectations for what a referring physician will have already done: the exam, the documentation, and in many cases the biopsy.

The AAFP document covers the standard diagnostic pathway: visual assessment of suspicious lesions, dermoscopy where available, and biopsy performed to confirm or exclude melanoma. On the treatment side, it addresses the management of confirmed cases, including the role of excision with appropriate margins and the referral routes to oncology for advanced disease.

What does the review not do?

The published summary does not introduce new trial data, new staging criteria or new drug approvals. It is a consolidation resource — a synthesis aimed at family physicians rather than a data release aimed at specialists. Dermatology readers looking for updates to AJCC staging, sentinel node biopsy thresholds or adjuvant immunotherapy regimens will need to go to the primary literature and specialty guidelines.

That said, consolidation documents carry real weight in practice. They drive what happens in the exam room months before a patient is handed off. When a national body like the AAFP publishes on melanoma, it signals where primary care's attention is — and where the gaps between primary detection and specialist management still sit.

Where does this fit in the broader picture?

Melanoma remains the skin cancer with the highest mortality risk, and early detection is the variable that most changes outcomes. Reviews aimed at first-contact clinicians keep the pressure on that front end: know what to look at, know when to biopsy, know when to refer.

For dermatology practices, the practical takeaway is a referral-flow question. If family physicians are reading and applying this guidance, dermatology clinics can expect referrals with more consistent lesion documentation and, ideally, earlier presentations. Coordinating around a shared diagnostic standard is cheaper for everyone than reconciling inconsistent workups after the fact.

The AAFP's review is available through the organization's clinical resources, and it adds a primary-care perspective that specialty clinicians can use to anticipate — and improve — what arrives at their door.

Expect continued releases of this kind as professional bodies push early-detection messaging toward first-contact clinicians; the next measurable signal will be whether referral patterns and stage-at-presentation data shift in the years ahead.